An Open-Label, Single-Dose Clinical Study to Evaluate Pharmacokinetics of MK-8507 in Participants With Mild or Moderate Hepatic Impairment.
Latest Information Update: 15 May 2024
At a glance
- Drugs Ulonivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 09 May 2024 Planned End Date changed from 3 Apr 2025 to 10 Sep 2025.
- 09 May 2024 Planned primary completion date changed from 3 Apr 2025 to 10 Sep 2025.
- 09 May 2024 Planned initiation date changed from 29 Oct 2024 to 7 Apr 2025.